Conference Coverage

The Latest

Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants

Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.

By Polly Clayden for HIV i-Base

Raltegravir-Based Third-Line ART in Children and Adolescents

Five case studies from Uganda showed good responses in children and adolescents receiving raltegravir-based third-line ART.

By Polly Clayden for HIV i-Base

Raltegravir in HIV-Exposed Neonates

Daily raltegravir was well tolerated and met pharmacokinetic targets in full term HIV-exposed infants at high risk of infection, in a study presented at the 8th International Workshop on HIV Paediatrics.

By Polly Clayden for HIV i-Base

Once-Daily Raltegravir and Dolutegravir-Based Dual-Drug Regimen Show Promise

On behalf of IFARA, Fred Schaich spoke with Pedro Cahn, M.D., Ph.D., about two late-breaking studies presented at this year's International AIDS Conference and about global funding for HIV.

By Barbara Jungwirth

Once-Daily Raltegravir at Last Available: Week 48 Results From ONCEMRK Study

After many years of research, Merck now have a once-daily formulation of raltegravir -- though it requires two tablets with a higher milligram dose.

By Simon Collins for HIV i-Base

Promising Results for New, Simpler Dosing of Raltegravir (Isentress)

The ONCEMRK study compared a new once-a-day dosing of raltegravir to the current twice-a-day dosing schedule. This simplification could help individuals improve adherence to their regimens which may result in better suppression of HIV over time.

By Project Inform

Pharmacokinetics of Antiretrovirals in Pregnancy: Rilpivirine, Etravirine and Raltegravir

Three posters at CROI 2015 described pharmacokinetics of antiretrovirals in pregnancy for rilpivirine, etravirine and raltegravir. None of the studies suggested that dose adjustment is required.

By Polly Clayden for HIV i-Base

Significantly Less BMD Loss With HIV Therapy That Doesn't Contain Tenofovir/Emtricitabine

Raltegravir was associated with significantly less bone mineral density (BMD) loss in the hip and lumbar spine than was tenofovir/emtricitabine when used as part of a first-line antiretroviral therapy regimen that contained darunavir boosted with rit...

By Theo Smart

Atazanavir, Raltegravir and Darunavir Virologically Equivalent in Naive Patients but Significant Differences for Tolerability: Results From ACTG 5257

Primary results from the ACTG 5257 study shifted the assumed relative parity between three of the preferred first-line combinations in US DHHS guidelines. Raphael Landovitz from University of California Los Angeles, presented results at CROI 2014 fro...

By Simon Collins for HIV i-Base

Raltegravir Superior to Boosted Protease Inhibitors as First-Line Treatment

U.S. treatment guidelines equally recommend first-line treatment regimens that include either a non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (Sustiva, Stocrin); one of two ritonavir (Norvir)-boosted protease inhibitors (PIs), ata...

By Josep M. Llibre, M.D., Ph.D. and Benjamin Young, M.D., Ph.D.